EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Anti-CGRP monoclonal antibodies for chronic migraine with medication-overuse headache: a conservative meta-analysis

Luana Miyahira Makita iD, Gabriela das Graças Dos Santos Carolino iD, Yuri Gubitose de Souza iD, Heloísa Carneiro Brito iD, Mariana Oliveira iD, Giovana Schlichta Adriano Kojima iD, Milena Ramos Tomé iD, Júlia Dos Santos Monteiro iD, Yasmin Bastos Faller iD, Elcio Juliato Piovesan iD, Mario Fernando Prieto Peres iD

Arquivos de Neuro-Psiquiatria · 01.03.2026 · 84 (03) · 001-009

DOI: 10.1055/s-0046-1817018 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Arquivos de Neuro-Psiquiatria, erschienen am 01.03.2026. Verfasst von Luana Miyahira Makita und 10 weiteren Autor:innen. Beteiligte Einrichtung: Universidade Federal do Paraná, Setor de Ciências da Saúde, Departamento de Medicina, Curitiba PR, Brazil. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Headache Disorders, Secondary, Migraine Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic migraine (CM) is often complicated by medication-overuse headache (MOH), worsening disability. Although withdrawal of overused medications is recommended, adherence is poor and relapse is frequent. Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway may offer an effective preventive option without requiring discontinuation, but current evidence is limited by few and heterogeneous randomized controlled trials (RCTs). To systematically assess the efficacy and safety of anti-CGRP mAbs in treating CM with MOH (CM + MOH) under a conservative approach. The PubMed, Embase, and Cochrane Central databases were searched for RCTs comparing anti-CGRP mAbs with placebo in adults with CM + MOH. The primary outcome was the mean change in monthly migraine days (MMDs) at 3 months. The secondary outcomes included acute medication use, disability, drug overuse resolution, response rate, and adverse events (AEs). Random-effects models with Sidik-Jonkman estimator and Knapp-Hartung adjustments pooled effect sizes. We included seven RCTs, totalling 3,094 patients. Anti-CGRP mAbs significantly reduced MMDs (mean difference [MD] = -0.35; 95%CI: -0.43 to -0.26) and acute medication use (MD = -0.35; 95%CI: -0.51 to -0.19) compared with placebo. Higher rates, of ≥ 50%, of response (risk ratio [RR] = 1.94; 95%CI: 1.60–2.34) and drug overuse resolution (RR = 1.38; 95%CI: 1.04–1.83) were observed, with no significant increase in AEs (RR = 1.09; 95%CI: 0.85–1.40). Anti-CGRP mAbs were effective and well tolerated in CM + MOH, representing a viable alternative, especially for patients unable to discontinue acute medications. Further research should assess long-term outcomes and subgroup effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCalcitonin Gene-Related PeptideHeadache Disorders, SecondaryMigraine DisordersHumansChronic DiseaseRandomized Controlled Trials as TopicTreatment Outcome

Substanzen

Antibodies, MonoclonalCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Universidade Federal do Paraná, Setor de Ciências da Saúde, Departamento de Medicina, Curitiba PR, Brazil.
  • Faculdade de Ciências Médicas e da Saúde de Juiz de Fora, Departamento de Medicina, Juiz de Fora MG, Brazil.
  • Faculdade de Medicina do ABC, Departamento de Medicina, Santo André SP, Brazil.
  • Universidade Federal da Paraíba, Departamento de Medicina, João Pessoa PB, Brazil.
  • Faculdade de Ensino Superior da Amazônia Reunida, Departamento de Medicina, Redenção PA, Brazil.
  • Universidade Federal de Campina Grande, Cajazeiras PB, Brazil.

ORCID-Profile: Luana Miyahira Makita, Gabriela das Graças Dos Santos Carolino, Yuri Gubitose de Souza, Heloísa Carneiro Brito, Mariana Oliveira, Giovana Schlichta Adriano Kojima, Milena Ramos Tomé, Júlia Dos Santos Monteiro, Yasmin Bastos Faller, Elcio Juliato Piovesan, Mario Fernando Prieto Peres

Zitieren

APA

Makita, L. M., Carolino, G. D. G. D. S., Souza, Y. G., Brito, H. C., Oliveira, M., Kojima, G. S. A., Tomé, M. R., Monteiro, J. D. S., Faller, Y. B., Piovesan, E. J., & Peres, M. F. P. (2026). Anti-CGRP monoclonal antibodies for chronic migraine with medication-overuse headache: a conservative meta-analysis. Arquivos de Neuro-Psiquiatria, 84(03), 001-009. https://doi.org/10.1055/s-0046-1817018

Vancouver

Makita LM, Carolino GDGDS, Souza YG, Brito HC, Oliveira M, Kojima GSA, et al. Anti-CGRP monoclonal antibodies for chronic migraine with medication-overuse headache: a conservative meta-analysis. Arquivos de Neuro-Psiquiatria. 2026;84(03):001-009. doi:10.1055/s-0046-1817018

BibTeX
@article{Makita2026,
  author = {Makita, Luana Miyahira and Carolino, Gabriela das Graças Dos Santos and Souza, Yuri Gubitose de and Brito, Heloísa Carneiro and Oliveira, Mariana and Kojima, Giovana Schlichta Adriano and Tomé, Milena Ramos and Monteiro, Júlia Dos Santos and Faller, Yasmin Bastos and Piovesan, Elcio Juliato and Peres, Mario Fernando Prieto},
  title = {Anti-CGRP monoclonal antibodies for chronic migraine with medication-overuse headache: a conservative meta-analysis},
  journal = {Arquivos de Neuro-Psiquiatria},
  year = {2026},
  volume = {84},
  number = {03},
  pages = {001--009},
  doi = {10.1055/s-0046-1817018}
}
Kostenlos starten →